A new study led by Harvard School of Public researchers provides a novel explanation as to why some tuberculosis cells are inherently more difficult to treat with antibiotics.
The discovery, which showed that the ways mycobacteria cells divide and grow determine their susceptibility to treatment with drugs, could lead to new avenues of drug development that better target tuberculosis cells. The study appeared Thursday in an advance online edition of Science.
Tuberculosis is an infectious disease that kills more than 1.5 million people annually. It is a difficult disease to treat; people are prescribed a combination of antibiotics to be taken daily for six to nine months, a regimen that is hard for patients to follow and for nurses and doctors to administer. Even after beginning appropriate treatment, it appears that some of the infectious cells survive for long periods of time.
The researchers set out to determine what distinguishes a cell that lives from one that dies. They designed a unique microfluidic chamber in which they grew Mycobacterium smegmatis cells (which behave similarly to Mycobacterium tuberculosis cells) and filmed their growth with a live-cell imaging system.
The researchers thought that the M. smegmatis cells would divide evenly into similar-sized daughter cells, as bacteria such as E. coli do. Instead, they were surprised to find that the M. smegmatis daughter cells were incredibly diverse, with highly variable sizes and growth rates. They found that this diversity arises because M. smegmatis grow in an unusual fashion, elongating from only one end. When an asymmetric mother cell divides, it creates daughter cells that are very different from one another in fundamental ways, including their growth properties.